Novartis, PTC Therapeutics

Novartis failed to persuade a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...
Novartis’ latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG (NOVN – Research Report) on December 4 and set a price target of ...
Local Spotlight: Managing high bad cholesterol. High bad cholesterol is a risk factor for a common type of heart disease, yet ...
Novartis has announced the acquisition of San Diego-based Kate Therapeutics in a deal valued at $1.1bn, enhancing its ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...
In a case-based competition, participants will be able to solve real-life problems in collaboration with experts from ...